FDA approves landmark pancreatic cancer drug that’s shown to improve survival - AP News

FDA approves landmark pancreatic cancer drug that’s shown to improve survival  AP News

US drug agency approves breakthrough treatment for pancreatic cancer

Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers.

F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

By Gina Kolata and Rebecca Robbins

FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease - WSJ

FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease  WSJ

US approves new treatment for pancreatic cancer

The US Food and Drug Administration announced its approval for a drug that could double the survival time of some patients for a type of cancer that has, historically, been difficult to treat.

FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives

In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.

By Daniel Wu

FDA gives expedited approval to new groundbreaking pancreatic cancer drug

FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancer The US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease. FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumor growth in more than 90% of pan...

By Associated Press

FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double

Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug - CNN

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug  CNN

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

The drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.

Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. - Barron's

Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.  Barron's

Vesselon Issued Patent and New Data Changes the Therapeutic Index of Antibody-Based Drugs - Morningstar

Vesselon Issued Patent and New Data Changes the Therapeutic Index of Antibody-Based Drugs  Morningstar

FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results

The therapy is a brand new targeted drug for the disease which experts have labelled as a substantial breakthrough following doubling of survival time in a trial.

By Victoria Forster, Contributor

Meet Ashka Shah, the 17-year-old New York student who studied how a cancer-driving protein

A student from New York has pioneered a groundbreaking technique aimed at halting the growth of cancer cells. This research focuses on a crucial protein linked to the rapid development of tumors. By inhibiting the harmful activity of this protein, her method preserves the viability of healthy cells. She gained national acclaim as a finalist in a prestigious science competition, illuminating a promising new pathway for precision cancer therapies.

By TOI World Desk

Revolution Medicines gets FDA approval for targeted pancreatic cancer drug

The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.

White House is said to announce drug pricing deals with biotechs

Oppenheimer raises Revolution stock price target on FDA approval

By Investing.com

Barry Manilow Taking a Break From Las Vegas Residency After Canceling Shows: ‘We All Need To Sit Down and Shut Up’

The singer who had surgery for stage 1 lung cancer in December, promised to be back on stage in October.

By Gil Kaufman

FDA approves groundbreaking pancreatic cancer drug

FDA approves landmark pancreatic cancer drug that's shown to improve survival

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer - Taiwan News

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer  Taiwan News

U.S. FDA approves landmark pancreatic cancer drug that’s shown to improve survival

The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer.

By Deborah Okailey Quarcoo